Selected research
Market Structure
Global Liquid Embolic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Liquid Embolic Agent market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Liquid Embolic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Liquid Embolic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Liquid Embolic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Liquid Embolic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Liquid Embolic Agent include Saikesaisi Holding, Johnson & Johnson, Medtronic, Meril Life, BlackSwan Vascular and Balt Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Liquid Embolic Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Liquid Embolic Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Liquid Embolic Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liquid Embolic Agent market size, projected growth trends, production technologies, key applications, and end-use industries.
Liquid Embolic Agent Segment by Company
Saikesaisi Holding
Johnson & Johnson
Medtronic
Meril Life
BlackSwan Vascular
Balt Group
Liquid Embolic Agent Segment by Type
EVOH Type
nBCA Type
Other
Liquid Embolic Agent Segment by Application
Cerebral Arteriovenous Malformations (AVMs)
Dural Arteriovenous Fistulas (DAVFs)
Other
Liquid Embolic Agent Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liquid Embolic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liquid Embolic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liquid Embolic Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Liquid Embolic Agent market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liquid Embolic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liquid Embolic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Liquid Embolic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- EVOH Type
- nBCA Type
- Other
Applications
- Cerebral Arteriovenous Malformations (AVMs)
- Dural Arteriovenous Fistulas (DAVFs)
- Other
Companies covered
- Saikesaisi Holding
- Johnson & Johnson
- Medtronic
- Meril Life
- BlackSwan Vascular
- Balt Group
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Liquid Embolic Agent Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Liquid Embolic Agent Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Liquid Embolic Agent Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Liquid Embolic Agent Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Liquid Embolic Agent Market Dynamics
- 2.1 Liquid Embolic Agent Industry Trends
- 2.2 Liquid Embolic Agent Industry Drivers
- 2.3 Liquid Embolic Agent Industry Opportunities and Challenges
- 2.4 Liquid Embolic Agent Industry Restraints
3 Liquid Embolic Agent Market by Manufacturers
- 3.1 Global Liquid Embolic Agent Revenue by Manufacturers (2021-2026)
- 3.2 Global Liquid Embolic Agent Sales by Manufacturers (2021-2026)
- 3.3 Global Liquid Embolic Agent Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Liquid Embolic Agent Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Liquid Embolic Agent Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Liquid Embolic Agent Manufacturers, Product Type & Application
- 3.7 Global Liquid Embolic Agent Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Liquid Embolic Agent Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Liquid Embolic Agent Players Market Share by Revenue in 2025
- 3.8.3 2025 Liquid Embolic Agent Tier 1, Tier 2, and Tier 3
4 Liquid Embolic Agent Market by Type
- 4.1 Liquid Embolic Agent Type Introduction
- 4.1.1 EVOH Type
- 4.1.2 nBCA Type
- 4.1.3 Other
- 4.2 Global Liquid Embolic Agent Sales by Type
- 4.2.1 Global Liquid Embolic Agent Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Liquid Embolic Agent Sales by Type (2021-2032)
- 4.2.3 Global Liquid Embolic Agent Sales Market Share by Type (2021-2032)
- 4.3 Global Liquid Embolic Agent Revenue by Type
- 4.3.1 Global Liquid Embolic Agent Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Liquid Embolic Agent Revenue by Type (2021-2032)
- 4.3.3 Global Liquid Embolic Agent Revenue Market Share by Type (2021-2032)
5 Liquid Embolic Agent Market by Application
- 5.1 Liquid Embolic Agent Application Introduction
- 5.1.1 Cerebral Arteriovenous Malformations (AVMs)
- 5.1.2 Dural Arteriovenous Fistulas (DAVFs)
- 5.1.3 Other
- 5.2 Global Liquid Embolic Agent Sales by Application
- 5.2.1 Global Liquid Embolic Agent Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Liquid Embolic Agent Sales by Application (2021-2032)
- 5.2.3 Global Liquid Embolic Agent Sales Market Share by Application (2021-2032)
- 5.3 Global Liquid Embolic Agent Revenue by Application
- 5.3.1 Global Liquid Embolic Agent Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Liquid Embolic Agent Revenue by Application (2021-2032)
- 5.3.3 Global Liquid Embolic Agent Revenue Market Share by Application (2021-2032)
6 Global Liquid Embolic Agent Sales by Region
- 6.1 Global Liquid Embolic Agent Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Liquid Embolic Agent Sales by Region (2021-2032)
- 6.2.1 Global Liquid Embolic Agent Sales by Region (2021-2026)
- 6.2.2 Global Liquid Embolic Agent Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Liquid Embolic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Liquid Embolic Agent Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Liquid Embolic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Liquid Embolic Agent Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Liquid Embolic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Liquid Embolic Agent Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Liquid Embolic Agent Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Liquid Embolic Agent Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Liquid Embolic Agent Revenue by Region
- 7.1 Global Liquid Embolic Agent Revenue by Region
- 7.1.1 Global Liquid Embolic Agent Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Liquid Embolic Agent Revenue by Region (2021-2026)
- 7.1.3 Global Liquid Embolic Agent Revenue by Region (2027-2032)
- 7.1.4 Global Liquid Embolic Agent Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Liquid Embolic Agent Revenue (2021-2032)
- 7.2.2 North America Liquid Embolic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Liquid Embolic Agent Revenue (2021-2032)
- 7.3.2 Europe Liquid Embolic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Liquid Embolic Agent Revenue (2021-2032)
- 7.4.2 Asia-Pacific Liquid Embolic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Liquid Embolic Agent Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Liquid Embolic Agent Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Saikesaisi Holding
- 8.1.1 Saikesaisi Holding Company Information
- 8.1.2 Saikesaisi Holding Business Overview
- 8.1.3 Saikesaisi Holding Liquid Embolic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Saikesaisi Holding Liquid Embolic Agent Product Portfolio
- 8.1.5 Saikesaisi Holding Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Company Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Liquid Embolic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Johnson & Johnson Liquid Embolic Agent Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Medtronic
- 8.3.1 Medtronic Company Information
- 8.3.2 Medtronic Business Overview
- 8.3.3 Medtronic Liquid Embolic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Medtronic Liquid Embolic Agent Product Portfolio
- 8.3.5 Medtronic Recent Developments
- 8.4 Meril Life
- 8.4.1 Meril Life Company Information
- 8.4.2 Meril Life Business Overview
- 8.4.3 Meril Life Liquid Embolic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Meril Life Liquid Embolic Agent Product Portfolio
- 8.4.5 Meril Life Recent Developments
- 8.5 BlackSwan Vascular
- 8.5.1 BlackSwan Vascular Company Information
- 8.5.2 BlackSwan Vascular Business Overview
- 8.5.3 BlackSwan Vascular Liquid Embolic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 BlackSwan Vascular Liquid Embolic Agent Product Portfolio
- 8.5.5 BlackSwan Vascular Recent Developments
- 8.6 Balt Group
- 8.6.1 Balt Group Company Information
- 8.6.2 Balt Group Business Overview
- 8.6.3 Balt Group Liquid Embolic Agent Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Balt Group Liquid Embolic Agent Product Portfolio
- 8.6.5 Balt Group Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Liquid Embolic Agent Value Chain Analysis
- 9.1.1 Liquid Embolic Agent Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Liquid Embolic Agent Production Mode & Process
- 9.2 Liquid Embolic Agent Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Liquid Embolic Agent Distributors
- 9.2.3 Liquid Embolic Agent Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst